VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 38
- +3 vs. Q2 2024
- Portfolio value
- $1.91B
- +$339.0M (+21.6%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| TENXTenax Therapeutics, Inc. | COM NEW | 208,333 | $720.8K | <0.1% | +208,333 | New | History |
| TILInstil Bio, Inc. | COM NEW | 33,177 | $2.23M | 0.1% | +33,177 | New | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,555,556 | $3.00M | 0.2% | 00.0% | Unchanged | History |
| CASIFCASI Pharmaceuticals, Inc. | ORD SHS | 987,259 | $6.08M | 0.3% | +875,573+784.0% | Added | History |
| CABACabaletta Bio, Inc. | COM | 1,563,952 | $7.38M | 0.4% | 00.0% | Unchanged | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 750,000 | $7.51M | 0.4% | 00.0% | Unchanged | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 2,023,166 | $8.21M | 0.4% | −4,000,000−66.4% | Reduced | History |
| IPSCCentury Therapeutics, Inc. | COM | 5,389,259 | $9.22M | 0.5% | 00.0% | Unchanged | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 1,467,048 | $10.3M | 0.5% | 00.0% | Unchanged | History |
| ARVNArvinas, Inc. | COM | 454,450 | $11.2M | 0.6% | −173,338−27.6% | Reduced | History |
| TRVITrevi Therapeutics, Inc. | COM | 3,422,656 | $11.4M | 0.6% | +190.0% | Added | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,345,780 | $15.5M | 0.8% | 00.0% | Unchanged | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 9,000,000 | $18.1M | 0.9% | 00.0% | Unchanged | History |
| MRSNMersana Therapeutics, Inc. | COM | 11,328,000 | $21.4M | 1.1% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 1,379,965 | $23.1M | 1.2% | 00.0% | Unchanged | History |
| ENGNenGene Therapeutics Inc. | COM | 3,565,841 | $23.5M | 1.2% | +739,858+26.2% | Added | History |
| ARTVArtiva Biotherapeutics, Inc. | COM | 1,609,569 | $24.9M | 1.3% | +1,609,569 | New | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 1,000,000 | $26.7M | 1.4% | −818,182−45.0% | Reduced | History |
| AQSTAquestive Therapeutics, Inc. | COM | 5,555,555 | $27.7M | 1.4% | 00.0% | Unchanged | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 3,410,058 | $28.4M | 1.5% | 00.0% | Unchanged | History |
| ATXSAstria Therapeutics, Inc. | COM | 3,458,645 | $38.1M | 2.0% | −150,000−4.2% | Reduced | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 706,131 | $40.6M | 2.1% | 00.0% | Unchanged | History |
| ERASErasca, Inc. | COM | 16,216,216 | $44.3M | 2.3% | 00.0% | Unchanged | History |
| ORICOric Pharmaceuticals, Inc. | COM | 4,394,527 | $45.0M | 2.4% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 907,963 | $45.4M | 2.4% | −355,251−28.1% | Reduced | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 4,400,000 | $47.6M | 2.5% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,744,373 | $47.8M | 2.5% | −350,000−16.7% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 5,684,167 | $61.4M | 3.2% | 00.0% | Unchanged | History |
| PHVSPharvaris N.V. | COM | 3,395,606 | $62.9M | 3.3% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 6,249,731 | $72.4M | 3.8% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 3,085,620 | $75.6M | 4.0% | +3,085,620 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 2,173,913 | $78.1M | 4.1% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 2,685,448 | $79.0M | 4.1% | 00.0% | Unchanged | History |
| APLTApplied Therapeutics, Inc. | COM | 9,825,000 | $83.5M | 4.4% | +282,129+3.0% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,882,709 | $88.3M | 4.6% | +380.0% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 4,026,331 | $102.8M | 5.4% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 12,762,462 | $111.0M | 5.8% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 8,493,321 | $498.9M | 26.1% | 00.0% | Unchanged | History |
Sold out since Q2 2024 (1)
Positions held at the end of Q2 2024 that are gone from this filing.